KLRSKalaris Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 17746
Ticker: KLRS
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2025-03-19
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: KLRS

Detail

Enriched 2026-08-14 20:47

Market cap: $93,791,625.14
Shares outstanding (class): 23,792,278
Shares outstanding (weighted): 23,804,981
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 20
Location: BERKELEY HEIGHTS, NJ
Homepage: https://www.kalaristx.com
Description: Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Market cap and share counts drift.

Funds holding this security

11 funds · 11 positions · $2.26M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$1.02M	0.00%	176,727 NS	FIGI
Simplify Propel Opportunities ETF Simplify Exchange Traded Funds	SURI	$504.4K	0.73%	87,426 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$419.0K	0.00%	72,619 NS	FIGI
Ultra-Small Company Market Fund Bridgeway Funds, Inc.	—	$129.8K	0.11%	22,500 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$50.2K	0.00%	8,699 NS	FIGI
Goldman Sachs Absolute Return Tracker Fund GOLDMAN SACHS TRUST	—	$48.6K	0.00%	8,430 NS	FIGI
VIP Disciplined Small Cap Portfolio Variable Insurance Products Fund II	—	$45.0K	0.01%	7,806 NS	FIGI
VANGUARD BALANCED INDEX FUND VANGUARD VALLEY FORGE FUNDS	—	$34.6K	0.00%	6,002 NS	FIGI
1290 VT Micro Cap Portfolio EQ Advisors Trust	—	$3.5K	0.00%	608 NS	FIGI
LVIP Dimensional U.S. Core Equity 2 Fund LINCOLN VARIABLE INSURANCE PRODUCTS TRUST	—	$778.95	0.00%	135 NS	FIGI
JNL/DFA U.S. Small Cap Fund JNL Series Trust	—	$455.83	0.00%	79 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERKLRS
FIGI_COMPOSITEBBG00P80SH34
FIGI_SHARE_CLASSBBG00P80SH43
CIK0001754068
ISINUS4829291065
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: The company is a therapeutics firm classified under SIC 2836 (biological products), indicating biotechnology.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.